You are here

Valneva

COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO

COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO

Fierce Biotech

Flag link:

Valneva takes COVID-19 vaccine candidate into Phase 3 trials

Valneva takes COVID-19 vaccine candidate into Phase 3 trials

Biopharma Reporter

clinical trials

Flag link:

Valneva and Pfizer start new Phase 2 study for Lyme disease vaccine candidate

Valneva and Pfizer start new Phase 2 study for Lyme disease vaccine candidate

Biopharma Reporter

clinical trials

Flag link:

Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

Drugs.com

clinical trials

Flag link:

Four Potential Biotech Market Movers to Watch Going into 2021

Four Potential Biotech Market Movers to Watch Going into 2021

BioSpace

Flag link:

Valneva signs manufacturing partner to produce adjuvant for COVID-19 vaccine

Valneva signs manufacturing partner to produce adjuvant for COVID-19 vaccine

Fierce Pharma

drug manufacturing

Flag link:

Valneva signs $1.6B supply, development agreement with UK for coronavirus vaccine hopeful

Valneva signs $1.6B supply, development agreement with UK for coronavirus vaccine hopeful

Fierce Pharma

Flag link:

Amid Covid-19 hunt, Pfizer adds Lyme disease vaccine in $308M deal with Valneva

Amid Covid-19 hunt, Pfizer adds Lyme disease vaccine in $308M deal with Valneva

Endpoints

Flag link:

Lyme Disease Vaccine Could Be Ready In 4 to 5 Years

Lyme Disease Vaccine Could Be Ready In 4 to 5 Years

Forbes

Flag link:

Can a new Lyme disease vaccine overcome a history of distrust and failure?

Can a new Lyme disease vaccine overcome a history of distrust and failure?

Stat

drug development

Flag link:

Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report

Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report

Fierce Pharma

Flag link: